重组人γ-干扰素对慢性乙型肝炎血清肝纤维化标志的影响

Observations on the influence of recombinant IFN-γon the fibrosis serum markers of chronic hepatitis B

目的 研究重组人γ干扰素 (IFN γ)治疗慢性乙型肝炎肝纤维化的治疗作用。方法 40例慢性乙型肝炎患者随机分为A、B两组 ,A组采用IFN γ和常规药物联合治疗 ;B组仅采用常规药物治疗 ,疗程为 9个月。用放射免疫法测定治疗前、治疗 3、6、9个月及停药后 3个月血清HA、LN、PⅢNP及Col Ⅳ水平。结果 A组血清HA、LN、PⅢNP及Col Ⅳ随治疗时间逐渐降低 ,至 9个月到最低点 ,而B组无明显降低。有效率A组为 61.1% (11/18,脱落 2例 ) ,B组为 10 .0 % (2 /2 0 ) ,两组有显著性差异 (P =0 .0 0 4)。

Objective To observe the changes of fibrosis serum markers and safety of recombinant IFN γ in treatment of patients with fibrosis of hepatitis B. Methods Forty patients with chronic hepatitis B were randomly divided into group A and B. Patients in both groups received conventional drugs for 9 months, however, patients in group A also received IFN γ concomitently for 9 months. Serum HA, LN, PⅢNP and Col Ⅳ were measured in the above patients by radioimmunoassay at 0,3,6,9 months and three months after cessation of treatment.Results The serum levels of HA、LN、PⅢNP and Col Ⅳ were gradually decreased till nadir at 9 month after treatment in group A, but there were no change during the period in group B. The rates of efficacy were 61.1%(11/18, 2 cases were lost to follow up) in group A and 10.0% in group B, there was significant difference between the two groups ( P =0.004).Conclusion IFN γ combined with conventional drugs is effective in treatment of fibrosis of chronic hepatitis B.